Cautious. Merck trades at a fair 16.5× forward P/E with solid Value Compounder fundamentals (59/100), but growth deceleration and heavy Keytruda dependency (~46% of revenue, patent expiry 2028) create material near-term vulnerability. Leadership alignment is reasonable (70.3/100), but the patent cliff demands successful pipeline execution to sustain returns.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Merck & Company, Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 58/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Merck & Company, Inc. (MRK) at 58/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. Merck trades at a fair 16.5× forward P/E with solid Value Compounder fundamentals (59/100), but growth deceleration and heavy Keytruda dependency (~46% of revenue, patent expiry 2028) create material near-term vulnerability. Leade
MRK's current Stocky Verdict is 58/100, placing it in the "Cautious" band. This composite combines a 59/100 Compounder score, 70/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Merck & Company, Inc. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Merck & Company, Inc. scores 70/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Merck & Company, Inc.'s Vulnerability Profile scores 50/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Merck & Company, Inc..
Sign up free and unlock the full analysis on MRK — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for MRK in the app.
